USMIRC myeloma News Letter_ issue 1
Jan 2024
Is it time for Pentuplet treatment use as induction therapy in Ultra- High-Risk Myeloma?
FDA Approves Elranatamab for Multiple Myeloma: A New Option for Relapse Myeloma Patients or a Teclistamab Replicate?
Tweet of the USMIRC group
Meet our Joint scientific council co- chair of USMIRC
Myelomatous pleural effusion in penta-RRMM post- BCMA treatment failure
USMIRC group work: Assessing the Impact of BCMA-Directed Therapies in Penta-RRMM in the Real World!
Treatment induced peripheral neuropathy in myeloma